NCT04018261View on ClinicalTrials.gov

Virus-specific Activated T Lymphocytes From a Donor in Hematopoietic Progenitor Transplanted Patients

PHASE1/PHASE2CompletedINTERVENTIONAL
Enrollment

26

Participants

Timeline

Start Date

July 4, 2019

Primary Completion Date

October 18, 2021

Study Completion Date

October 18, 2021

Conditions
CMV ViremiaImmunosuppression-related Infectious Disease
Interventions
DRUG

Activated T-Lymphocytes

Activated T-Lymphocytes will be infused intravenously in a single-dose

Trial Locations (7)

46026

Hospital Universitario La Fe, Valencia

08916

ICO Badalona, Badalona

08950

Hospital Sant Joan de Déu, Esplugues de Llobregat

08908

ICO l'Hospitalet, L'Hospitalet de Llobregat

08025

Hospital de la Santa Creu i Sant Pau, Barcelona

08035

Hospital Vall d'Hebron, Barcelona

08036

Hospital Clinic i Provincial de Barcelona, Barcelona

All Listed Sponsors
collaborator

Vall d'Hebron Institute of Oncology

OTHER

collaborator

Hospital Universitario La Fe

OTHER

lead

Banc de Sang i Teixits

OTHER

NCT04018261 - Virus-specific Activated T Lymphocytes From a Donor in Hematopoietic Progenitor Transplanted Patients | Biotech Hunter | Biotech Hunter